Biology subjects

Isaikina, P.

Publications and source records attributed to Isaikina, P..

4 recordsLinked to original sources

bioRxiv2026

Photoswitchable optoGPCRs for reversible control of Gs and arrestin signalling

OptoGPCRs are light-activatable G protein-coupled receptors (GPCRs) used for optogenetic control of physiological processes. Most existing optoGPCRs are based on monostable opsins, which are limited by photobleaching and irreversibility. The bistable jumping spider rhodopsin 1 (JSR1) carrying the single point mutant S199F introduces a [~]150 nm spectral separation between the active and inactive states, enabling bidirectional control with distinct wavelengths of light. Here, we show that JSR1-S199F demonstrates robust, light-reversible arrestin recruitment and Gq/i protein activity. We then engineered JSR1-S199F-based optoGPCRs with Gs protein activity, expanding the limited repertoire of bistable Gs-coupled opsins. Specifically, we present optoDRD1, a chimeric optoGPCR that redirects the native Gq/i protein activity of JSR1 towards the Gs pathway of the dopamine D1 receptor (DRD1). Through systematic screening of intracellular domain combinations, we identified an optimal chimeric configuration comprising ICL2, ICL3, helix 8, and the C-terminus from DRD1. The resulting optoGPCR is activated by violet light ({lambda}max = 397 nm) and deactivated by green light ({lambda}max = 531 nm) at physiologically relevant light intensities. A single violet light pulse drives sustained Gs signalling for several hours, while green light deactivation enables precise signal termination at any timepoint. OptoDRD1 closely mimics wild-type DRD1 signalling kinetics and G protein selectivity. Compared to JellyOp, the only previously characterised natively Gs-coupled opsin, optoDRD1 shows higher signal amplitude and reversibility over multiple light cycles. We further demonstrate optoDRD1s utility for optogenetic control of Gs-regulated processes in vitro, including insulin secretion in human {beta}-cells and signalling modulation in a neuronal cell line, supporting its potential for in vivo applications. The biochemical stability and known structure of JSR1 make it a robust scaffold for this rational engineering and for future biophysical characterization. Together, optoDRD1 and JSR1-S199F expand the optoGPCR toolkit and open new opportunities for dissecting dopaminergic signalling, Gs-mediated physiology, and GPCR signalling pharmacology.

synthetic biology↗

bioRxiv2024

A high-resolution analysis of arrestin2 interactions responsible for CCR5 endocytosis

Clathrin-mediated endocytosis (CME) is crucial for regulating G protein-coupled receptors (GPCRs) via phosphorylation-dependent arrestin interactions. Despite detailed structural knowledge on the arrestin interactions with phosphorylated tails of GPCRs, the interplay between receptor phosphorylation and arrestin coupling to the CME machinery is not well understood, in particular due to the weakness and dynamics of the individual molecular interactions. Here we have characterized the interactions of arrestin2, which is activated by the phosphorylated C-terminus of the human chemokine receptor 5 (CCR5), with the main protein constituents of CME, namely clathrin and AP2 by solution NMR spectroscopy, biochemical and cellular assays. The NMR analysis revealed that arrestin2 interacts weakly with clathrin through a single binding site, independent of arrestin2 activation. In contrast, the arrestin2-AP2 interaction is stronger, requires arrestin2 activation by the CCR5 phospho-tail, and depends quantitatively on its degree of phosphorylation. These in vitro results are corroborated by cellular assays, which show that the chemokine-induced formation of a long-lived CCR5-arrestin2 internalization complex depends strongly on the interaction of arrestin2 with AP2, but not with clathrin. Taken together, these findings provide quantitative, atom-scale insights on the first steps of CCR5 endocytosis.

biochemistry↗

bioRxiv2022

A key GPCR phosphorylation motif discovered in arrestin2-CCR5 phosphopeptide complexes

The two non-visual arrestin isoforms, arrestin2 and arrestin3 recognize and bind hundreds of G protein-coupled receptors (GPCRs) with different phosphorylation patterns leading to distinct functional outcomes. The impact of phosphorylation on arrestin interactions has been well studied only for very few GPCRs. Here we have characterized the interactions between the phosphorylated CC chemokine receptor 5 (CCR5) and arrestin2. We detected several new CCR5 phosphorylation sites, which are necessary for stable complex formation with arrestin2. Crystal structures of arrestin2 in apo form and in complexes with CCR5 C-terminal phosphopeptides together with NMR spectroscopy, biochemical and functional assays revealed three phosphoresidues in a pXpp motif that are essential for the arrestin2 interactions and activation. The same phosphoresidue cluster is present in other receptors, which form stable complexes with arrestin2. We propose that the identified pXpp motif is responsible for robust arrestin2 recruitment in many GPCRs. An analysis of available sequences, structural and functional information on other GPCR*arrestin interactions suggests that a particular arrangement of phosphoresidues within the GPCR intracellular loop 3 and C-terminal tail determines arrestin2 and 3 isoform specificity. Taken together, our findings demonstrate how multi-site phosphorylation controls GPCR*arrestin interactions and provide a framework to probe the intricate details of arrestin activation and signaling. One-sentence summaryA structural and functional analysis of arrestin2 in apo form and complexes with several CCR5 phosphopeptides reveals key phosphorylation sites responsible for stable GPCR*arrestin interactions and their contributions to CCR5-arrestin2 function.

biophysics↗

bioRxiv2020

Structural basis of the activation of the CC chemokine receptor 5 by a chemokine agonist

The human CC chemokine receptor 5 (CCR5) is a G protein-coupled receptor (GPCR) that plays a major role in inflammation and is involved in the pathology of cancer, HIV, and COVID-19. Despite its significance as a drug target, the activation mechanism of CCR5, i.e. how chemokine agonists transduce the activation signal through the receptor, is yet unknown. Here, we report the cryo-EM structure of wild-type CCR5 in an active conformation bound to the chemokine super-agonist [6P4]CCL5 and the heterotrimeric Gi protein. The structure provides the rationale for the sequence-activity relation of agonist and antagonist chemokines. The N-terminus of agonist chemokines pushes onto an aromatic connector that transmits activation to the canonical GPCR microswitch network. This activation mechanism differs significantly from other CC chemokine receptors that bind shorter chemokines in a shallow binding mode and have unique sequence signatures and a specialized activation mechanism. One-sentence summaryThe structure of CCR5 in complex with the chemokine agonist [6P4]CCL5 and the heterotrimeric Gi protein reveals its activation mechanism

biophysics↗